Metropolis Healthcare Limited (NSE: METROPOLIS, BSE: 542650) is a Mumbai, Maharashtra-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹11,002 Cr, it ranks #566 by market cap among the 6,137 Indian listed companies on FinBizNet, and #2 of 18 in Medical Diagnostic Centres. At ₹522.95 (as of 25 Oct 2026), the share price is 14.1% below its 52-week high of ₹609.05 and 26.9% above its 52-week low of ₹412.25. The share price is up 7.3% over one year and down 8.3% over three months.
| Current Price | ₹522.95 |
|---|---|
| Market Cap | ₹11,002 Cr |
| NSE Symbol | METROPOLIS |
| BSE Code | 542650 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Services > Medical Diagnostic Centres |
| P/E Ratio | 56.7 |
| Return on Equity | 13.37% |
| Return on Assets | 8.36% |
| 52-Week Range | ₹412.25 – ₹609.05 |
| 1-Year Price Change | +7.3% |
| 3-Month Price Change | -8.3% |
| Beta (1Y) | 0.85 |
| Dividend Yield | 0.38% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.metropolisindia.com |
| Revenue | ₹450 Cr |
|---|---|
| Net Profit | ₹57 Cr |
| Net Margin | 12.6% |
| EPS (Basic) | ₹2.73 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standal
1. Pathology Service-This segment provides pathology and related healthcare services.
1. Pathology Service-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Vijaya Diagnostic Centre Limited | ₹14,231 Cr | 81.5 | 19.70% | ₹231 Cr | +40.7% |
| Metropolis Healthcare Limited | ₹11,002 Cr | 56.7 | 13.37% | ₹450 Cr | +7.3% |
| Throcare Technologies Ltd | ₹7,737 Cr | 46.3 | 28.74% | ₹240 Cr | +8.9% |
| Dr. Agarwal'S Eye Hospital Ltd | ₹2,465 Cr | 34.5 | 25.22% | — | +20.0% |
| Krsnaa Diagnostics Ltd | ₹1,730 Cr | 16.6 | 10.89% | ₹236 Cr | -38.8% |
| SURAKSHA DIAGNOSTIC LIMITED | ₹1,597 Cr | 48.2 | 13.84% | ₹88 Cr | -0.3% |
| Gaudium IVF and Women Health Limited | ₹738 Cr | 25 | 16.08% | ₹19 Cr | — |
| Chandan Healthcare Limited | ₹583 Cr | 21.5 | — | ₹81 Cr | — |
| Star Imaging And Path Lab Limi | ₹136 Cr | 6.2 | — | — | -43.0% |
Listed by market capitalisation. Ratios are shown for context only.
Metropolis Healthcare Limited is trading at ₹522.95, with a market capitalisation of ₹11,002 Cr.
Metropolis Healthcare Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).
Metropolis Healthcare Limited has a P/E of 56.7 and a return on equity of 13.37%.
Metropolis Healthcare Limited is listed on the NSE under the symbol METROPOLIS and on the BSE under the scrip code 542650.
Metropolis Healthcare Limited's share price is up 7.3% over one year and down 8.3% over three months. Its 52-week range is ₹412.25 to ₹609.05.
In Q1 FY27, Metropolis Healthcare Limited reported revenue of ₹450 Cr and net profit of ₹57 Cr, with basic EPS of ₹2.73 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.